ISSN: 2578-6512
Chief
Cholesterol metabolism and therapeutic innovations
University Toulouse
France
Tel: +33-0-582741626
Dr. Marc Poirot is first class research director (DR1) at the Institut National de la Sante et de la Recherche Médicale (INSERM). He heads the team 'Cholesterol metabolism and therapeutic innovations' (Cancer Research Center of Toulouse, France). Dr. Poirot has skills in medicinal chemistry, biochemistry, cell biology and drug development. He received a PhD in Chemical Biology (1991) from the University of Toulouse (France). He did a post-doc at Sanofi in 1991 before becoming tenured at INSERM. He was visiting scientist from 1993 to 1996 in the laboratory of Dr. Stoney S Simons Jr (NIDDK/NIH, Bethesda, USA) to study steroid hormone receptors. Since then, his research has focused on the elucidation the mechanisms of action of the anti-tumor drug tamoxifen, which led to the definition of the importance of the microsomal anti-estrogen binding site (AEBS) in its pharmacology. This observation led him to study the deregulations of cholesterol metabolism in cancers. His laboratory identified a new metabolic pathway centered on cholesterol oxides that generates the first steroidal alkaloid discovered to date and which displays tumor suppressor properties. His main research interests are the study of deregulations in sterol metabolism in cancers, the identification and the characterization of new sterol metabolites involved in these deregulations, and the determination of their metabolic fate and the determination their molecular mechanisms of action.
